Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
AbbVie scores FDA approval for arthritis treatment upadacitinib
AbbVie has been betting on its new products upadacitinib for RA and Skyrizi for psoriasis to combat Humira’s decline. ... If approved in Europe, AbbVie could begin to reclaim Humira’s lost ground in RA.
Latest news
-
Gilead strikes $5.1bn deal to bolster ties with Galapagos
Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s ... well-regarded JAK1 inhibitor
-
Citryll snares €15m backing for its autoimmune disease NETs
New approach to tackling diseases such as lupus, RA. Dutch biotech Citryll has raised 15m ($17m) in first-round financing to help advance its new therapeutic approach to autoimmune diseases.
-
GSK pushes rheumatoid arthritis antibody into phase 3
Head-to-head trial necessary in crowded field. GlaxoSmithKline has opted to take its rheumatoid arthritis (RA) candidate otilimab into phase 3, despite mixed phase 2 results. ... Even combination treatment with multiple targeted drugs only achieves
-
AbbVie’s upadacitinib tops Humira again in arthritis trial
Firm says pipeline drug only JAK inhibitor to show superiority. AbbVie‘s JAK inhibitor upadacitinib works better than its blockbuster Humira in keeping rheumatoid arthritis (RA) patients in clinical remission over ... in RA, “a majority of patients
-
FDA approves AbbVie’s psoriasis blockbuster-to-be Skyrizi
That JAK1-selective inhibitor is intended to treat those with immune-meditated disease, including rheumatoid arthritis (RA), a therapy area where the drug has so far aced all of its clinical
More from news
Approximately 9 fully matching, plus 149 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
-
Behavioural design - it's a no-brainer
Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest from PMHub
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study.
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... The patient profile and unmet needs in RA. Profile of physicians prescribing JAKS.
-
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients.
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
shape the RA market of tomorrow and how companies can best position themselves for future success. ... Topics to be covered include:. The European RA market. Current status and market situation of JAK inhibitors (key EU5 countries).
-
Report: Living with RA (EU, Japan and Canada) 2019 reports
Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in the 5 EU markets (France, Germany, Italy, Spain, UK) and 55 patients in ... The report is an update on the existing Living with RA
More from PMHub
Approximately 2 fully matching, plus 22 partially matching documents found.
Featured jobs
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Cello Health
Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
